[{"id":"65eed3dd-6e61-408e-98c2-7b567021d3e7","acronym":"KEYNOTE-G05","url":"https://clinicaltrials.gov/study/NCT06784648","created_at":"2025-02-25T16:11:37.790Z","updated_at":"2025-02-25T16:11:37.790Z","phase":"Phase 1/2","brief_title":"Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT06784648 - KEYNOTE-G05","lead_sponsor":"BioInvent International AB","biomarkers":" PD-1 • FCGR2A","pipe":"","alterations":" ","tags":["PD-1 • FCGR2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • BI-1607"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/11/2024","start_date":" 12/11/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-01-20"},{"id":"b0de5b72-b291-4f7b-b7dc-a88cb52730a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00104858","created_at":"2021-01-18T00:20:23.943Z","updated_at":"2024-07-02T16:36:58.223Z","phase":"Phase 2","brief_title":"Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT00104858","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • FCGR2A • FCGR3A • FCGR2B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • FCGR2A • FCGR3A • FCGR2B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • fludarabine IV • cyclosporin A microemulsion • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 12/01/2004","start_date":" 12/01/2004","primary_txt":" Primary completion: 03/30/2018","primary_completion_date":" 03/30/2018","study_txt":" Completion: 03/30/2018","study_completion_date":" 03/30/2018","last_update_posted":"2019-07-11"},{"id":"9de1f7e7-ee3c-4744-8a41-ac93419cdd06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02132182","created_at":"2021-01-18T09:53:26.826Z","updated_at":"2024-07-02T16:37:09.347Z","phase":"","brief_title":"Monocyte Phenotypic and Functional Differences","source_id_and_acronym":"NCT02132182","lead_sponsor":"Duke University","biomarkers":" CCR7 • FCGR2A • CCR2 • FCGR2B","pipe":"","alterations":" ","tags":["CCR7 • FCGR2A • CCR2 • FCGR2B"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/23/2017","primary_completion_date":" 03/23/2017","study_txt":" Completion: 03/23/2017","study_completion_date":" 03/23/2017","last_update_posted":"2018-06-29"},{"id":"7ef03ec1-b18c-4029-b154-49641bcbc76a","acronym":"MUTEX","url":"https://clinicaltrials.gov/study/NCT01450319","created_at":"2021-01-18T06:01:10.414Z","updated_at":"2025-02-25T14:49:30.598Z","phase":"Phase 2","brief_title":"Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype","source_id_and_acronym":"NCT01450319 - MUTEX","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" EGFR • KRAS • B2M • FCGR2A • FCGR2B • KIR2DS4","pipe":" | ","alterations":" KRAS mutation • EGFR expression • RAS mutation","tags":["EGFR • KRAS • B2M • FCGR2A • FCGR2B • KIR2DS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2016-11-28"}]